Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
Radiological progression was delayed by 5 months in one trial, but its design does not allow reliable analysis of survival. Numerous, sometimes serious, adverse effects occurred.